ZIM Laboratories Limited (ZIMLAB.NS)
INR 112.56
(0.39%)
INR 112.56
(0.39%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 983.6 Million INR | 79.75% |
| 2022 | 547.19 Million INR | 9.67% |
| 2021 | 498.93 Million INR | -38.35% |
| 2020 | 809.27 Million INR | -10.56% |
| 2019 | 904.85 Million INR | 17.97% |
| 2018 | 767.05 Million INR | -3.73% |
| 2017 | 796.77 Million INR | -1.02% |
| 2016 | 805.01 Million INR | -15.46% |
| 2015 | 952.25 Million INR | 3.43% |
| 2014 | 920.67 Million INR | 41.1% |
| 2013 | 652.51 Million INR | 80.02% |
| 2012 | 362.46 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 98.84 Million INR | -89.95% |
| 2023 Q1 | 64.2 Million INR | -88.27% |
| 2023 FY | 983.6 Million INR | 79.75% |
| 2023 Q3 | 171.67 Million INR | -63.45% |
| 2023 Q4 | 983.6 Million INR | 472.94% |
| 2023 Q2 | 469.68 Million INR | 631.54% |
| 2022 FY | 547.19 Million INR | 9.67% |
| 2022 Q4 | 547.19 Million INR | 509.13% |
| 2022 Q3 | 89.83 Million INR | -84.62% |
| 2022 Q2 | 583.89 Million INR | 1074.42% |
| 2022 Q1 | 49.71 Million INR | -90.04% |
| 2021 FY | 498.93 Million INR | -38.35% |
| 2021 Q1 | 83.51 Million INR | -89.68% |
| 2021 Q2 | 850.52 Million INR | 918.4% |
| 2021 Q3 | 50.05 Million INR | -94.11% |
| 2021 Q4 | 498.93 Million INR | 896.69% |
| 2020 Q2 | 619.34 Million INR | 495.22% |
| 2020 Q1 | 104.05 Million INR | -88.5% |
| 2020 Q3 | 53.97 Million INR | -91.29% |
| 2020 Q4 | 809.27 Million INR | 1399.32% |
| 2020 FY | 809.27 Million INR | -10.56% |
| 2019 FY | 904.85 Million INR | 17.97% |
| 2019 Q1 | 41.52 Million INR | -94.59% |
| 2019 Q2 | 766.82 Million INR | 1746.56% |
| 2019 Q3 | 68.15 Million INR | -91.11% |
| 2019 Q4 | 904.85 Million INR | 1227.63% |
| 2018 Q4 | 767.05 Million INR | 891.46% |
| 2018 FY | 767.05 Million INR | -3.73% |
| 2018 Q3 | 77.36 Million INR | -88.96% |
| 2018 Q2 | 701.04 Million INR | 4463.17% |
| 2018 Q1 | 15.36 Million INR | -98.07% |
| 2017 Q1 | 5.06 Million INR | 0.0% |
| 2017 Q4 | 796.77 Million INR | 0.0% |
| 2017 FY | 796.77 Million INR | -1.02% |
| 2016 FY | 805.01 Million INR | -15.46% |
| 2015 FY | 952.25 Million INR | 3.43% |
| 2014 FY | 920.67 Million INR | 41.1% |
| 2013 FY | 652.51 Million INR | 80.02% |
| 2012 FY | 362.46 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Sigachi Industries Limited | 859.94 Million INR | -14.379% |
| Ind-Swift Limited | 9.5 Billion INR | 89.656% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 70.184% |
| Sakar Healthcare Limited | 790.93 Million INR | -24.359% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 73.368% |
| Innova Captab Limited | 2.33 Billion INR | 57.853% |
| Divi's Laboratories Limited | -39.77 Billion INR | 102.473% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 119.623% |
| Morepen Laboratories Limited | -231.17 Million INR | 525.482% |
| Mankind Pharma Limited | -1.74 Billion INR | 156.259% |
| Sequent Scientific Limited | 4.17 Billion INR | 76.461% |
| Wanbury Limited | 1.1 Billion INR | 11.056% |
| Laurus Labs Limited | 24.35 Billion INR | 95.962% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 84.025% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 134.602% |
| Alembic Limited | 66.9 Million INR | -1370.26% |
| Hikal Limited | 7.96 Billion INR | 87.654% |
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 74.557% |
| Neuland Laboratories Limited | -214.05 Million INR | 559.503% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 65.135% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 122.953% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 189.313% |
| Themis Medicare Limited | 764.96 Million INR | -28.582% |
| RPG Life Sciences Limited | -364.7 Million INR | 369.702% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 74.857% |
| Lupin Limited | 19.38 Billion INR | 94.926% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 495.352% |
| Wockhardt Limited | 18.27 Billion INR | 94.616% |
| Vaishali Pharma Limited | 119.13 Million INR | -725.621% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 62.341% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 170.766% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 96.367% |
| FDC Limited | -57.75 Million INR | 1803.151% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 92.383% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -719.404% |
| Eris Lifesciences Limited | 13.8 Billion INR | 92.876% |
| Venus Remedies Limited | -267.7 Million INR | 467.428% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 184.958% |
| Par Drugs and Chemicals Limited | -366.53 Million INR | 368.349% |
| Caplin Point Laboratories Limited | -5.5 Billion INR | 117.859% |
| Shilpa Medicare Limited | 9.06 Billion INR | 89.155% |
| Albert David Limited | -278.36 Million INR | 453.345% |
| Ajanta Pharma Limited | -954.9 Million INR | 203.006% |
| Hester Biosciences Limited | 2.29 Billion INR | 57.062% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -578.46% |
| Solara Active Pharma Sciences Limited | 10.03 Billion INR | 90.195% |
| Gufic Biosciences Limited | 3.19 Billion INR | 69.208% |
| Windlas Biotech Limited | -273.04 Million INR | 460.242% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 141.891% |
| Aarey Drugs & Pharmaceuticals Limited | 297.57 Million INR | -230.535% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -0.799% |
| Granules India Limited | 9.28 Billion INR | 89.409% |
| Aarti Drugs Limited | 5.54 Billion INR | 82.272% |
| Bal Pharma Limited | 1.26 Billion INR | 22.156% |
| Alkem Laboratories Limited | -1.6 Billion INR | 161.116% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 101.357% |
| Lincoln Pharmaceuticals Limited | -127.63 Million INR | 870.62% |
| Medicamen Biotech Limited | 160.31 Million INR | -513.541% |
| Unichem Laboratories Limited | 931.91 Million INR | -5.546% |
| Bafna Pharmaceuticals Limited | 229.93 Million INR | -327.779% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 5432.343% |
| Valiant Laboratories Limited | 649.9 Million INR | -51.347% |
| Orchid Pharma Limited | -1.31 Billion INR | 174.865% |
| Medico Remedies Limited | 78.67 Million INR | -1150.18% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 123.684% |
| Ipca Laboratories Limited | 11.41 Billion INR | 91.383% |
| Brooks Laboratories Limited | 49.48 Million INR | -1887.681% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -2028.506% |
| Piramal Enterprises Limited | 491.39 Billion INR | 99.8% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 96.91% |
| NATCO Pharma Limited | -5.81 Billion INR | 116.909% |
| Suven Life Sciences Limited | -1.63 Billion INR | 160.244% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 49.113% |
| Strides Pharma Science Limited | 23.25 Billion INR | 95.771% |
| Indoco Remedies Limited | 6.47 Billion INR | 84.812% |
| Alpa Laboratories Limited | 35.36 Million INR | -2681.45% |
| Lasa Supergenerics Limited | 205.79 Million INR | -377.944% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 204.439% |